Advertisement

JM8 Development and Clinical Projects

  • A. H. Calvert
  • S. J. Harland
  • K. R. Harrap
  • E. Wiltshaw
  • I. E. Smith
Chapter
Part of the Developments in Oncology book series (DION, volume 17)

Abstract

Since its introduction in the early 1970’s cisplatin has become established as one of the major cytotoxic drugs used in the treatment of cancer. Of particular note are its application in combination therapy to the treatment of testicular cancer (1) and in the treatment of ovarian cancer (2). The majority of patients with testicular teratoma are probably cured of their disease. Cisplatin is probably the most active single agent in the treatment of ovarian cancer producing an overall response rate in excess of 50% and a complete response rate of 20–30% (2). In our hands a group of 27 patients treated with high dose cisplatin for stage III ovarian carcinoma and followed for a minimum of 3 years had an actuarial survival of 35% at 3 and 4 years (3).

Keywords

Ovarian Cancer Electron Paramagnetic Resonance Platinum Complex Testicular Teratoma Dichloro Platinum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Newlands ES, Rustin GJS, Begent RHJ, Parker D, Bagshawe KD: Further advances in the management of malignant teratomas of the testis and other sites The Lancet Vol 1(1983) No 8331 951–984Google Scholar
  2. 2.
    Wiltshaw E and Kroner T: Phase II study of cis-dichlorodiammine platinum (II) (NSC 119875) in advanced adenocarcinoma of the ovary Cancer Treat. Rep. (60) 55–60, 1976PubMedGoogle Scholar
  3. 3.
    Wiltshaw E, Evans BD, et al: A randomised trial of high-dose cisplatin versus low low dose cisplatin and chlorambucil in carcinoma of the ovary proc. 14th Int. Congress of Chemotherapy, Vienna 1983 (in press)Google Scholar
  4. 4.
    Prestayko AW, D’Aoust JC, Issel IF, Crooke ST: Cisplatin (cis-diammine dichloro platinum (II)) Cancer Treat. Rev. (6) 17–39, 1979PubMedCrossRefGoogle Scholar
  5. 5.
    Krakoff IH: Nephrotoxicity of cis-dichlorodiammineplatinum (II) Cancer Treat. Rep. (63) 1527–1532, 1979Google Scholar
  6. 6.
    Macauley VM, Begent RHJ, Phillips ME, Newlands ES: Prophylaxis against hypomagnesemia induced by cis-platinum combination chemotherapy Cancer Chemother. Pharmacol (in press)Google Scholar
  7. 7.
    Reddel RR, Kefford RF, Grant JM, Coates AS Fox RM Tattersall MHN: Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration Cancer Treat. Rep. (66) 19, 1982PubMedGoogle Scholar
  8. 8.
    Harrap KR: Platinum Analogues:Criteria for selection In: Cancer Chemotherapy Muggia FM (ed) Martinus Nijhoff, Massachusets (in press)Google Scholar
  9. 9.
    Harrap KR, Jones M, Wilkinson CR, Clink H McD, Sparrow S, Mitchley BCV, Clarke S, Veasey A: Antitumour, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: Cisplatin Current status and New developments, Prestayko AW, Crooke ST, and Carter SK (eds) New York Academic Press 1980 ppp 193-212Google Scholar
  10. 10.
    Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JW, Peckham MJ and Harrap KR: Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II Cancer Chemother. Pharmacol (9) 140–147, 1982Google Scholar
  11. 11.
    Chantier C, Garnett ES, Parsons V: Glomerular filtration rate measurement in man by the single injection methods using Cr 51 EDTA Clin. Sci. Mol. Med. (37) 169, 1969Google Scholar
  12. 12.
    Koeller JM, Earhart RH, Davis TE, Trump DL, Tormey DC: Phase I trial of carboplatin (NSC 241240) by bolus intravenous injection Proc. 74th Meeting of The Am. Assoc. for Cancer Res. (24) 162, 1983Google Scholar
  13. 13.
    Kaplan S, Joss R, Sessa C, Goldhirsch A, Cattaneo M, Cavalli F: Phase I trials of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in solid tumours. Proc 74th Meeting of The Am. Assoc. for Cancer Res. (24) 132, 1983Google Scholar
  14. 14.
    Curt CA, Grygiel JJ, Weiss R, Corden B, Ozols R, Tell D Collins J,, Myers CE: A phase I and pharmacokinetic study of CBDCA (NSC 241240) Proc. of the 19th Meeting of The Am. Soc. of Clin. Oncology (2) 21, 1983Google Scholar
  15. 15.
    Nicaise C, Rozencweig M, Beer M, Piccart M, Crespeigne N, Anton Aparicio L, Van Rijmenant M Lenaz L, Kenis Y: Phase I clinical trial of carboplatin (CBDCA) administered at a five-day schedule Proc 74th Meeting of The Am. Assoc. for Cancer Res. (24) 164, 1983Google Scholar
  16. 16.
    Egorin MJ, Van Echo DA, Whitacre MY, Olman EA, Aisner J: Phase I study and clinical pharmacokinetics of carboplatin (CBDCA) (NSC 241240) Proc. 19th Meeting of The Am. Soc. of Clin. Oncology (2) 28, 1983Google Scholar
  17. 17.
    Priego V, Luc V, Bonnern E, Rabman A, Smith F, Schein P, Woolley P: A phase I study and pharmacology of diammine (1,1) cyclobutane dicarboxylato (2-1-0) platinum (CBDCA) administered on a weekly schedule Proc. 19th Meeting of The Am. Soc. of Clin. Oncology (2) 30, 1983Google Scholar
  18. 18.
    Evans BD, Raju S, Calvert AH, Harland SJ, Wiltshaw E: A phase II study of JM8, a new platinum analogue in advanced ovarian carcinoma Cancer Treat. Rep. (in press) 1983Google Scholar
  19. 19.
    Calvert AH, Baker JW, Dalley VM, Harland SJ, Jones AC, Staffurth J: Phase II trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA, JM8) in patients with carcinoma of the ovary not previously treated with cisplatin Proc. 4th Int. Symp. on Platinum Coordination Complexes In Cancer Chemotherapy, Vermont 1983Google Scholar
  20. 20.
    Harland SJ, Smith IE, Smith N, Alison DL, Calvert AH: Phase II study of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (JM(, CBDCA) in carcinoma of the bronchus Proc. 4th Int. Symp. on Platinum Coordination Complexes in Cancer Chemotherapy, Vermont, USA 1983Google Scholar
  21. 21.
    Wiltshaw E, Evans BD, Jones AC, Baker JW, Calvert AH: JM8, successor to cisplatin in advanced ovarian cancer? Lancet 1(1983) (No 8324) p 587PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • A. H. Calvert
  • S. J. Harland
  • K. R. Harrap
  • E. Wiltshaw
  • I. E. Smith

There are no affiliations available

Personalised recommendations